Paclitaxel drug delivery systems

Expert Opinion on Drug Delivery

Volumn 10, Issue 3, 2013, Pages 325-340

  Zhang, Zhiping ^a,d   Mei, Lin ^b,d   Feng, Si Shen ^c,d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Suzhou GenePharma Co Ltd   (China)

Author keywords

Cancer nanotechnology; Drug delivery systems; Drug formulation; Nanomedicine; Pharmaceutical nanotechnology; Taxanes

Indexed keywords

CYPHER DRUG; DENDRIMER; DOCETAXEL; LIPOSOME; PACLITAXEL; POLYMER; PRODRUG; RAPAMYCIN; SOLID LIPID NANOPARTICLE; TAXUS DRUG; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; HUMAN; HYDROGEL; IC 50; MICELLE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; STENT THROMBOSIS; SUSTAINED DRUG RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; PACLITAXEL; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 84873887585     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.752354     Document Type: Review

References (100)

1. Rowinsky EK. Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 1993;15:25-37
2. Wani MC, Taylor HL, Wall ME, et al. Plant anti-tumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7
3. Deconinck E, Sohier J, De Scheerder I. Pharmaceutical aspects of drug eluting stents. J Pharm Sci 2008;97:5047-60
4. Sonia M, Cusidó RM, Mirjalili MH, et al. Production of the anticancer drug taxol in Taxus baccata suspension cultures. Process Biochem 2011;46:23-34
5. Guenard D, Gueritte-Voegelein F, Poiter P. Taxol and taxotere: discovery, chemistry and structure activity relationship. Acc Chem Res 1993;26:160-7
6. Sun L, Simmerling C, Ojima I. Recent advances in the study of the bioactive conformation of taxol. Chem Med Chem 2009;4:719-31
7. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28
8. Kingston DG. Recent advances in the chemistry of Taxol. J Nat Prod 2000;63:726-34 (Pubitemid 30395547)
9. Nicolaou KC, Dai WM, Guy RK. Chemistry and biology of taxol. Angew Chem Int Ed Engl 1994;33:15-44 (Pubitemid 24986738)
10. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125-41 (Pubitemid 32423718)
11. Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 2005;1:107-14
12. Paik PK, James LP, Riely GJ, et al. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion. Cancer Chemother Pharmacol 2011;68:1331-7
13. Testa B. Prodrug research: futile or fertile? Biochem Pharmacol 2004;68:2097-106 (Pubitemid 39446137)
14. Ettmayer P, Amidon G. L, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404 (Pubitemid 38580074)
15. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J Med Chem 2006;49:7253-69 (Pubitemid 44913386)
16. Moktan S, Ryppa C, Kratz F, et al. A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. Invest New Drugs 2012;30:236-48
17. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Eur J Pharm Biopharm 2004;57:313-18
18. Buescher JM, Margaritis A. Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries. Crit Rev Biotechnol 2007;27:1-19 (Pubitemid 46425931)
19. Langer CJ, O'Byrne KJ, SocinskiMA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008;3:623-30 (Pubitemid 351787307)
20. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98:1608-13 (Pubitemid 351684693)
21. O'Brien ME, Socinski MA, Popovich AY, et al. Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT- 2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008;3:728-34
22. Erez R, Segal E,Miller K, et al. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel. Bioorg Med Chem 2009;17:4327-35
23. Wang Y, Xin D, Liu K, et al. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009;20:2214-21
24. Li GL, Liu JY, Pang Y, et al. Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery. Biomacromolecules 2011;12(6):2016-26
25. Lim J, Lo ST, Hill S, et al. Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers. Mol Pharm 2012;9:404-12
26. Lin YS, Tungpradit R, Sinchaikul S, et al. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. J Med Chem 2008;51:7428-41
27. Elsadek B, Graeser R, Esser N, et al. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: An in vitro and in vivo evaluation study. Eur J Cancer 2010;46:3434-4
28. Quiles S, Raisch KP, Sanford L, et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem 2010;53:586-94
29. Eldar-Boock A, Miller K, Sanchis J, et al. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011;32:3862-74
30. Shan L, Cui S, Du C, et al. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33:146-62
31. Homsi J, Bedikian AY, Kim KB, et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 2009;19:238-42
32. Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011;22:787-93
33. Ke XY, Zhao BJ, Zhao X, et al. The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. Biomaterials 2010;31:5855-64
34. Abu Ajaj K, Biniossek ML, Kratz F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. Bioconjug Chem 2009;20:390-6
35. Xiao H, Song H, Yang Q, et al. A prodrug strategy to deliver cisplatin (IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 2012;33:6507-19
36. Jones M, Leroux J. Polymeric micelles - A new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48:101-11 (Pubitemid 29401986)
37. Wang F, Zhang D, Zhang Q, et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 2011;32:9444-56
38. Soga O, van Nostrum CF, Fens M, et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 2005;103:341-53 (Pubitemid 40342534)
39. Lian H, Sun J, Yu YP, et al. Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery. Int J Nanomed 2011;6:3323-34
40. Hamaguchi T, Kato K, Yasui H, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007;97:170-6 (Pubitemid 47057476)
41. Kato K, Chin K, Yoshikawa T, et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 2012;30:1621-7
42. Negishi T, Koizumi F, Uchino H, et al. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer 2006;95:601-6 (Pubitemid 44325900)
43. Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, a paclitaxel- incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005;92:1240-6 (Pubitemid 40604398)
44. Li H, Huo M, Zhou J, et al. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J Pharm Sci 2010;99:4543-53
45. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202 (Pubitemid 32522357)
46. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16
47. Lee SW, Yun MH, Jeong SW, et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J Control Release 2011;155:262-71
48. Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Del 2008;5:1003-25
49. Sharma A, Mayhew E, Bolcsak L, et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 1997;71:103-7 (Pubitemid 27158416)
50. Erez R, Segal E, Miller K, et al. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel. Bioorg Med Chem 2009;17:4327-35
51. Yang AZ, Li J, Xu HJ, et al. A study on antitumor effect of liposome encapsulated paclitaxel in vivo and in vitro. Bull Chin Cancer 2006;15:862-4
52. Mehta RR, Burke TG. Membrane biophysical parameters influencing anthracycline action. Anthracycline antibiotics. In: Priebe W, editor. Anthracycline Antibiotics. New York: American Chemical Society Publication; 2004:222-40
53. GuoW, Johnson JL, Khan S, et al. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatographytandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem 2005;336:213-20 (Pubitemid 40038019)
54. Fetterly GJ, Grasela TH, Sherman JW, et al. Pharmacokinetic/ pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 2008;14:5856-63
55. Gregoriadis G. Liposome technology. Interactions of liposomes with the biological milieu. Volume 3 Informa Healthcare; London: 2007
56. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012;7:49-60
57. Jain S, Kumar D, Swarnakar NK, et al. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 2012;33:6758-68
58. Qi J, Lu Y, Wu W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab 2012;13:418-28
59. Yuan H, Miao J, Du YZ, et al. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008;348:137-45 (Pubitemid 350266242)
60. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007;28:2137-46
61. Chen DB, Yang TZ, Lu WL. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001;49:1444-7
62. Dong XW, Mattingly CA, Tseng MT, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009;69:3918-26
63. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004;99:259-69 (Pubitemid 39222111)
64. Baek JS, So JW, Shin SC, et al. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-beta-cyclodextrin as an oral delivery system. Int J Mol Med 2012;30:953-9
65. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 2006;27:2285-91 (Pubitemid 41774539)
66. Feng SS, Zhao L, Zhang Z. Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem Eng Sci 2007;62:6641-8 (Pubitemid 47610671)
67. Zhang ZP, Lee SH, Gan CW, et al. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 2008;25:1925-35
68. Gan CW, Chien S, Feng SS. Enhancement of Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle Formulation. Curr Pharm Des 2011;16:2308-20
69. Zhang ZP, Tan SW, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012;33:4889-906
70. Zhang ZP, Feng SS. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006;27:262-70
71. Zhang ZP, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006;27:4025-33
72. Zhang ZP, Feng SS. Self-assembled nanoparticles of poly(lactide) - Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 2006;324:191-8
73. Zhang ZP, Yang XL, Feng SS. Copolymer technology for advanced nanomedicine. Nanomedicine 2011;6:583-7
74. Zhao LY, Feng SS. Enhanced oral bioavailability of paclitaxel formulated in Vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci 2010;99:3552-60
75. Feng SS, Mei L, Anitha P, et al. Poly (lactide) - vitamin E derivative/ montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009;30:3297-306
76. Huang L, Chen H, Zheng Y, et al. Nanoformulation of d-a-tocopheryl polyethylene glycol 1000 succinate-b-poly ("-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integr Biol 2011;3:951-1054
77. Zhang Y, Tang L, Sun L, et al. A novel paclitaxel-loaded poly ("-caprolactone)/ poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater 2010;6:2045-52
78. Mei L, Sun H, Jin X, et al. Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res 2007;24:955-62 (Pubitemid 46675396)
79. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly (lactide) vitamin E TPGS nanoparticles. Biomaterials 2008;29:2663-72
80. Liang C, Yang Y, Ling Y, et al. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem 2011;19:4057-66
81. Biricova V, Laznickova A. Dendrimers: analytical characterization and applications V. Bioorg Chem 2009;37:185-92
82. Tomalia DA, Dewald Jr. Dense star polymers having core, core branches, terminal groups. US4507466; 1985
83. Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine dendrimers: a comparison. Nanomedicine 2011;7:295-304
84. Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 2008;130:107-14
85. Ooya T, Lee J, Park K. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 2003;93:121-7 (Pubitemid 37421354)
86. Van der Hoeven BL, Pires NMM, Warda HM, et al. Drug-eluting stents: results, promises and problems. Int J Cardiol 2005;99:9-17 (Pubitemid 40261018)
87. Kivela A, Hartikainen J. Restenosis related to percutaneous coronary intervention has been solved? Ann Med 2006;38:173-87 (Pubitemid 43675583)
88. Parry TJ, Brosius R, Thygarajan R, et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharm 2005;524:19-29 (Pubitemid 41606808)
89. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8 (Pubitemid 46328299)
90. Bege N, Steinmu?ller SO, Kalinowski M, et al. Drug eluting stents based on Poly (ethylene carbonate): optimization of the stent coating process. Eur J Pharm Biopharm 2012;80:562-70
91. Feng SS, Zhao LY, Tang JT. Editorial: Nanomedicine for oral chemotherapy. Nanomedicine 2011;6:407-10
92. Abizaid A, Costa Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 2010;3:384-93
93. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002;54:3-12 (Pubitemid 34081178)
94. Zhao L, Zhu L, Liu F, et al. pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel. Int J Pharm 2011;410:83-91
95. Guo D, Xu CX, Quan JS, et al. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials 2009;30:4777-85
96. Bajaj G, Kim MR, Mohammed SI, et al. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release 2012;158:386-92
97. Qiao ZY, Zhang R, Du FS, et al. Multi-responsive nanogels containing motifs of ortho ester, oligo(ethylene glycol) and disulfide linkage as carriers of hydrophobic anti-cancer drugs. J Control Release 2011;152:57-66
98. Liu YT, Li K, Liu B, Feng SS. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010;31:9145-55
99. Zhao J, Mi Y, Liu YT, Feng SS. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials 2012;33:1948-58
100. Mi Y, Liu XL, Zhao J, et al. Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials 2012;33:7519-29